一項最新研究證實，簡單的血液檢測能夠分析患者的基因，能夠準確測定心臟移植排斥情況。

AlloMap檢測使用實時定量PCR(PCR)和運算法則來分析患者的基因表達。該檢測檢測出排斥情況，意味著較低的檢測成本就能夠十分可靠地鑒別出患者是否對心臟移植不會排斥。該檢測最主要優點是鑒別出低風險患者，這些患者能夠使用非創傷性方法進行監測和處理；以及那些需要積極使用強效免疫藥物的患者，這些藥物常常有嚴重的副作用。

Gene Expression Test Rules Out Transplant Rejection
 
A new study confirms that a simple blood test that analyzes a patient's genes can accurately detect the absence of heart transplant rejection.

The AlloMap test uses real-time polymerase chain reaction (PCR) and an algorithm to analyze the patient's gene expression. The test rules out rejection, meaning that a low test score very reliably identifies the transplant patient who is not rejecting the transplanted heart. The primary advantage of the test is to identify low-risk patients who can be monitored and managed using noninvasive methods and who may benefit from being more aggressively weaned off intensive immunosuppressive regimens that are associated with serious side effects.